Literature DB >> 2857333

Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate.

C Rouzioux, S Chamaret, L Montagnier, V Carnelli, G Rolland, P M Mannucci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2857333     DOI： 10.1016/s0140-6736(85)91043-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

Review 1.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

Review 2.  Factor VIII safety: plasma-derived versus recombinant products.

Authors:  Alessandro Gringeri
Journal:  Blood Transfus       Date:  2011-04-12       Impact factor: 3.443

3.  Absence of seroconversion for HTLV-III in haemophiliacs intensively treated with heat treated factor VIII concentrate.

Authors:  J van der Meer; S Daenen; G W van Imhoff; J T de Wolf; M R Halie
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-19

4.  Is major surgery in hemophiliac patients safe?

Authors:  W J Rudowski; R Scharf; J M Ziemski
Journal:  World J Surg       Date:  1987-06       Impact factor: 3.352

Review 5.  Transmission of human immunodeficiency virus (HIV/HTLV-III/LAV): a review.

Authors:  M van der Graaf; R J Diepersloot
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

Review 6.  Transfusion-associated acquired immunodeficiency syndrome.

Authors:  T A Peterman
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

7.  HTLV III antibodies and immunological alterations in hemophilia patients.

Authors:  E Seifried; G Pindur; H Stötter; F Porzsolt; H Rasche; V Erfle; R Hehlmann; H Heimpel
Journal:  Klin Wochenschr       Date:  1986-02-03

Review 8.  The development of virus-free labile blood derivatives--a review.

Authors:  A M Prince; B Horowitz; M S Horowitz; E Zang
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

9.  Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Authors:  J S McDougal; L S Martin; S P Cort; M Mozen; C M Heldebrant; B L Evatt
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

10.  Prevalence of antibodies to human T-lymphotropic virus-III (HTLV-III) in hemophiliacs and other patients chronically substituted with blood products.

Authors:  V Erfle; R Hehlmann; W Mellert; F D Goebel; H Rasokat; E Lechler; P Hellstern; M Köhler; E Seifried; H Heimpel
Journal:  Blut       Date:  1985-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.